DATA SHEET

PREMARIN®
(Conjugated estrogens)

NAME OF MEDICINE

PREMARIN 0.3 mg, 0.625 mg conjugated estrogens tablets. Conjugated estrogens (CE) is a mixture of natural estrogens (of equine origin) composed principally of the sodium salts of water soluble sulfate esters of estrone, equilin, and 17 alpha-dihydroequilin, together with smaller amounts of 17 alpha-estradiol, equilenin, and 17 alpha-dihydroequilenin, 17 beta-dihydroequilin, 17 beta-dihydroequilenin, 17 beta-estradiol and delta 8, 9-dihydroestrone.

DESCRIPTION

PREMARIN 0.3 mg tablets contain 0.3 mg CE as the active ingredient. PREMARIN 0.625 mg tablets contain 0.625 mg CE as the active ingredient. Each tablet also contains lactose monohydrate, hypromellose, magnesium stearate, macrogol 400, sucrose, microcrystalline cellulose, hyprollose, carnauba wax and Opacode WB NS-78-1-18011 white ink.

The colouring agent in PREMARIN 0.3 mg tablets is Opadry Green15B21511.

The colouring agent in PREMARIN 0.625 mg tablets is Opadry Maroon 03B16083.

PHARMACOLOGY

Pharmacodynamics

Estrogen production occurs primarily in the ovarian follicles in women from the menarche to the menopause and is important in the development and maintenance of the female urogenital system and secondary sex characteristics.

During the menopause the ovarian-estrogen production decreases and in postmenopausal women, when the ovaries have ceased to function, only a small amount of estrogen is still produced.

This decrease and eventual cessation of estrogen production in perimenopausal and postmenopausal women, respectively, may result in vasomotor symptoms (sweating, hot flushes) and atrophic vaginitis. In addition to relieving or eliminating these disorders, estrogen replacement therapy has also been demonstrated to retard or halt the postmenopausal bone mass loss (osteoporosis).

The pharmacological effects of CE are similar to those of endogenous estrogens.

Pharmacokinetics

Absorption

CE are soluble in water and are well absorbed from the gastrointestinal tract. The PREMARIN tablet releases CE slowly over several hours. Table 1 summarises the mean pharmacokinetic
parameters for CE following the administration of a single dose of 0.625 mg tablets to healthy postmenopausal women.

### Table 1: Pharmacokinetic profile of PREMARIN following a single dose of 0.625 mg tablets

<table>
<thead>
<tr>
<th>PK parameter</th>
<th>Arithmetic mean (%CV)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</th>
<th>t&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</th>
<th>AUC (ng•h/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total estrone</td>
<td>2.7 (43)</td>
<td>6.9 (25)</td>
<td>26.7 (33)</td>
<td>75 (52)</td>
<td></td>
</tr>
<tr>
<td>Baseline-adjusted total estrone</td>
<td>2.5 (45)</td>
<td>6.9 (25)</td>
<td>14.8 (35)</td>
<td>46 (48)</td>
<td></td>
</tr>
<tr>
<td>Total equilin</td>
<td>1.8 (56)</td>
<td>5.6 (45)</td>
<td>11.4 (31)</td>
<td>27 (56)</td>
<td></td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolism and inactivation occur primarily in the liver.

**Excretion**

Some estrogens are excreted into the bile; however, they are reabsorbed from the intestine and returned to the liver through the portal venous system. Water-soluble estrogen conjugates are strongly acidic and are ionised in body fluids, which favours excretion through the kidneys since tubular reabsorption is minimal.

### CLINICAL TRIALS

**Women’s Health Initiative studies**

The Women’s Health Initiative (WHI) enrolled approximately 27,000 predominantly healthy postmenopausal women in two sub-studies to assess the risks and benefits of CE (0.625 mg daily) alone or in combination with medroxyprogesterone acetate (MPA) (0.625 mg/2.5 mg daily) compared to placebo. The primary endpoint was incidence of coronary heart disease (CHD), i.e., non-fatal myocardial infarction (MI), silent MI and coronary death. The primary safety endpoint was incidence of invasive breast cancer. The study did not evaluate the effects of hormone replacement therapy (HRT) on menopausal symptoms.

The estrogen alone substudy was stopped early because an increased risk of stroke was observed and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints.

No overall effect on CHD events (defined as non-fatal MI, silent MI, or death, due to CHD) was reported in women receiving estrogen alone compared to placebo. Results of the estrogen alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3% White, 15.1% Black, 6.1% Hispanic, 3.6% Other) after an average follow-up of 6.8 years are presented in the table below.

In the estrogen alone substudy of WHI, there was no significant overall effect on the relative risk (RR) of CHD (RR 0.95, 95% nominal confidence interval (nCI) 0.78- 1.16); a slightly elevated RR of CHD was reported in the early follow-up period and diminished over time. There was no significant effect on the RR of invasive breast cancer (RR 0.80, 95% nCI 0.62-1.04) or colorectal cancer (RR 1.08, 95% nCI 0.75-1.55) reported. Estrogen use was associated with a statistically significant increased risk of stroke (RR 1.33, 95% nCI 1.05-1.68) and deep vein thrombosis (DVT) (RR 1.47, 95% nCI 1.06-2.06). The RR of pulmonary embolism (PE) (RR 1.37, 95% nCI 0.90-2.07) was not significantly increased. A statistically significant reduced risk of hip, vertebral and total fractures was reported with estrogen use (RR 0.65, 95%
nCI 0.45-0.94), (RR 0.64, 95% nCI 0.44-0.93), and (RR 0.71, 95% nCI 0.64-0.80), respectively. The estrogen alone substudy did not report a statistically significant effect on death due to other causes (RR 1.08, 95% nCI 0.88-1.32) or an effect on overall mortality risk (RR 1.04, 95% nCI 0.88-1.22).

These confidence intervals are unadjusted for multiple looks and multiple comparisons.

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk ET (estrogen therapy) vs. Placebo (95% nCI*)</th>
<th>Placebo (n = 5,429)</th>
<th>ET (n = 5,310)</th>
<th>Absolute Risk per 10,000 person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD events b</td>
<td>0.95 (0.78-1.16)</td>
<td>57</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI b</td>
<td>0.91 (0.73-1.14)</td>
<td>43</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>CHD death b</td>
<td>1.01 (0.71-1.43)</td>
<td>16</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Stroke b</td>
<td>1.33 (1.05-1.68)</td>
<td>33</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Ischaemic b</td>
<td>1.55 (1.19-2.01)</td>
<td>25</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Deep vein thrombosis b,d</td>
<td>1.47 (1.06-2.06)</td>
<td>15</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism b</td>
<td>1.37 (0.90-2.07)</td>
<td>10</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Invasive breast cancer b</td>
<td>0.80 (0.62-1.04)</td>
<td>34</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer e</td>
<td>1.08 (0.75-1.55)</td>
<td>16</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Hip fracture b</td>
<td>0.65 (0.45-0.94)</td>
<td>19</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Vertebral fractures b,d</td>
<td>0.64 (0.44-0.93)</td>
<td>18</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Lower arm/wrist fractures b,d</td>
<td>0.58 (0.47-0.72)</td>
<td>59</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Total fractures b,d</td>
<td>0.71 (0.64-0.80)</td>
<td>197</td>
<td>144</td>
<td></td>
</tr>
<tr>
<td>Death due to other causes c,e</td>
<td>1.08 (0.88-1.32)</td>
<td>50</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Overall mortality b,d</td>
<td>1.04 (0.88-1.22)</td>
<td>75</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>Global Index e</td>
<td>1.02 (0.92-1.13)</td>
<td>201</td>
<td>206</td>
<td></td>
</tr>
</tbody>
</table>

*Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.

b Results are based on centrally adjudicated data for an average follow-up of 7.1 years.

c Results are based on an average follow-up of 6.8 years.

d Not included in global index.

e All deaths, except from breast or colorectal cancer, definite/probable CHD, PE, or cerebrovascular disease.

A subset of the events was combined in a “global index,” defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.

Final adjudicated results for CHD events from the estrogen alone substudy, after an average follow-up of 7.1 years, reported no overall difference for primary CHD events (non-fatal MI, silent MI and CHD death) in women receiving CE compared with placebo.

**Women’s Health Initiative Memory Study**

In the estrogen alone Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, a population of 2,947 predominantly healthy hysterectomised women, aged 65-79 years, was randomised to CE (0.625 mg daily) or placebo. The relative risk of probable dementia for CE alone vs. placebo was 1.49 (95% CI 0.83-2.66). The absolute risk of probable dementia for CE alone vs. placebo was 37 vs. 25 cases per 10,000 women-years. Probable
dementia as defined in this study included Alzheimer’s disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and placebo group was AD. Since this study was conducted in women aged 65-79 years, it is unknown whether these findings apply to younger postmenopausal women (see PRECAUTIONS, Dementia).

INDICATIONS

Estrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

PREMARIN is indicated:

As replacement therapy for estrogen deficiency states associated with climacteric manifested by:

- moderate to severe vasomotor symptoms associated with the estrogen deficiency in natural and surgical menopause (sweating, hot flushes).
- atrophic vaginitis due to menopause.

When prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered.

There is no evidence that estrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.

For the prevention of postmenopausal osteoporosis.

When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and future fracture, in whom non-estrogen medications are not considered appropriate.

Hypoestrogenic states, e.g., female hypogonadism, primary ovarian failure or female castration.

See statements under PRECAUTIONS, General and Malignant neoplasm, Endometrial cancer and Cardiovascular risks and Dementia particularly when considering PREMARIN for long-term usage.

CONTRAINDICATIONS

PREMARIN is contraindicated in patients with:

- known or suspected pregnancy (see Use in pregnancy)
- known, suspected or past cancer of the breast
- known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer, endometrial hyperplasia)
- undiagnosed abnormal uterine bleeding
- active or history of confirmed venous thromboembolism (such as deep venous thrombosis, pulmonary embolism)
• active or history of arterial thromboembolic disease (e.g., stroke, myocardial infarction)
• severe uncontrolled hypertension
• other undiagnosed breast pathology
• active or chronic liver dysfunction or disease
• known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency)
• known or suspected hypersensitivity to the active ingredient or any excipients contained in PREMARIN.

PRECAUTIONS

General
Estrogen therapy and hormone therapy should not be initiated or continued to prevent or treat cardiovascular disease or dementia (see PRECAUTIONS, Cardiovascular risk and PRECAUTIONS, Dementia).

The benefits and risks of hormone therapy must always be carefully weighed, including consideration of the emergence of risks as therapy continues. In most circumstances, the risks of long-term hormone therapy outweigh the benefits. Estrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. In the absence of comparable data, the risks of hormone therapy should be assumed to be similar for all estrogens and estrogen/progestogen combinations.

If prescribing HRT for prevention of osteoporosis, the potential for increased cardiovascular, thrombotic and neoplastic adverse events must be considered.

Physical examination
A complete medical and family history should be obtained prior to initiating or reinstating any estrogen therapy and all prospective and current users of estrogen therapy should be advised of the risks and benefits of estrogens. Pre-treatment and subsequent physical examinations should include special reference to blood pressure, breasts, abdomen, and pelvic organs including histological endometrial assessment and/or papanicolaou smear. Before starting treatment pregnancy should be excluded. Periodic check-ups and careful benefit/risk evaluations should be undertaken in women receiving hormone therapy (see Malignant neoplasm, Endometrial cancer).

Combined estrogen and progestogen therapy
There are additional and/or increased risks that may be associated with the use of combination estrogen-progestogen therapy compared with using estrogen alone regimens. These include an increased risk of myocardial infarction, pulmonary embolism, invasive breast cancer and ovarian cancer.

Combined HRT should not be used for the long-term maintenance of general health, including the primary or secondary prevention of cardiovascular disease.

Estrogen or estrogenic compounds must not be used alone as HRT in women who have not had a hysterectomy.
**Cardiovascular risk**

Estrogen therapy has been reported to increase the risk of stroke and DVT.

Patients who have risk factors for thrombotic disorders should be kept under careful observation.

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolaemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of venous thromboembolism (VTE)), obesity, and systemic lupus erythematosus should be managed appropriately.

**Stroke**

In the estrogen alone substudy of the WHI, a statistically significant increased risk of stroke was reported in women receiving estrogen alone compared to women receiving placebo (45 vs. 33 per 10,000 person-years). The increase in risk was observed during year one and persisted. Should a stroke occur or be suspected, estrogens should be discontinued immediately (see CLINICAL TRIALS).

Patients who are at risk of developing migraines with aura may be at risk of ischemic stroke and should be kept under careful observation.

**Coronary Heart Disease**

In the estrogen alone substudy of WHI, no overall effect on coronary heart disease (CHD) events (defined as non-fatal MI, silent MI, or death due to CHD) was reported in women receiving estrogen alone compared to placebo (see CLINICAL TRIALS).

**Venous thromboembolism**

In the estrogen alone substudy of WHI, the risk of VTE (DVT and PE), was reported to be increased for women taking CE (30 vs. 22 per 10,000 person-years), although only the increased risk of DVT reached statistical significance (23 vs. 15 per 10,000 person-years). The increase in VTE risk was observed during the first two years. Should a VTE occur or be suspected, estrogens should be discontinued immediately (see CLINICAL TRIALS, Women’s Health Initiative studies).

Recognised risk factors for VTE include, but are not limited to, a personal history or family history of VTE, obesity and systemic lupus erythematosus.

The physician should be aware of the possibility of thrombotic disorders (including thrombophlebitis, retinal thrombosis, cerebral embolism and PE) during HRT and alert to their earliest manifestations. Should any of these occur or be suspected; HRT should be discontinued immediately. Patients who have risk factors for thrombotic disorders should be kept under careful observation.

If feasible, estrogens should be discontinued at least four to six weeks before surgery of the type associated with increased risk of thromboembolism or during periods of prolonged immobilisation.
Malignant neoplasms

Breast cancer

Studies involving the use of estrogens by postmenopausal women have reported inconsistent results on the risk of breast cancer.

In the estrogen alone substudy of WHI, after an average of 7.1 years of follow-up, CE (0.625 mg per day) was not associated with an increased risk of invasive breast cancer (RR 0.80, 95% nCI 0.62-1.04).

Some observational studies have reported an increased risk of breast cancer for estrogen alone therapy after several years of use. The risk increased with duration of use, and appeared to return to baseline within approximately five years after stopping treatment (only the observational studies have substantial data on risk of stopping).

The use of estrogen alone and estrogen plus progestogen has been reported to result in an increase in abnormal mammograms requiring further evaluation.

All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors and prior mammogram results.

Endometrial cancer

The use of unopposed estrogens in women with an intact uterus has been associated with an increased risk of endometrial cancer (see Exacerbation of other conditions).

The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after ET is discontinued.

Clinical surveillance of all women taking HRT is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal uterine bleeding. Where no pathological cause is found, alteration in the dose or cycling may be indicated (see DOSAGE AND ADMINISTRATION).

NOTE: In perimenopausal patients where the endometrium is still proliferative, persistence of the endometrial proliferation may occur during administration of HRT. An endometrial biopsy may be performed at the discretion of the attending physician.

Addition of a progestogen when a woman has not had a hysterectomy

Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lower incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.

There are, however, possible risks that may be associated with the use of progestogens in estrogen replacement regimens compared to estrogen alone regimens. These include an
increased risk of breast cancer, adverse effects on lipoprotein metabolism (e.g., lowering HDL, raising LDL) and impairment of glucose tolerance (see Combined estrogen and progestogen therapy).

**Ovarian cancer**

Ovarian cancer is much rarer than breast cancer.

Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking estrogen-only or combined estrogen-progestogen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.

Some other studies, including the WHI trial, suggest that the long-term use of combined HRTs may be associated with a similar or slightly smaller risk (see ADVERSE EFFECTS).

**Dementia**

The estrogen alone substudy of the WHIMS, conducted in women aged 65 to 79 years, reported an increased risk of developing probable dementia for CE alone compared to placebo (see CLINICAL TRIALS, Women’s Health Initiative Memory Study and Use in the elderly).

Therefore, in older women, the use of PREMARIN for the prevention of osteoporosis should only be considered for those who have failed on, or were intolerant of, non-estrogen medication.

**Gallbladder disease**

Women receiving PREMARIN should be monitored for gallbladder disease. A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in women receiving HRT has been reported.

**Uterine bleeding**

Certain patients may develop abnormal uterine bleeding (see Malignant neoplasm, Endometrial cancer).

**Fluid retention**

Because estrogens/progestogens may cause some degree of fluid retention, patients with conditions, which might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.

**Exacerbation of other conditions**

Estrogen therapy may cause an exacerbation of asthma, epilepsy, migraine with or without aura, diabetes mellitus with or without vascular involvement, otosclerosis, porphyria, systemic lupus erythematosus, and hepatic haemangioma and should be used with caution in women with these conditions.

Endometriosis may be exacerbated with administration of estrogen therapy. Addition of a progestogen should be considered in women who have undergone hysterectomy but are known to have residual endometriosis, since malignant transformation after estrogen only therapy has been reported.
Elevated blood pressure
In a small number of case reports, substantial increases in blood pressure during estrogen therapy have been attributed to idiosyncratic reactions to estrogens. In a large, randomised, placebo-controlled clinical trial a generalised effect of estrogen therapy on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.

Impaired liver function and history of cholestatic jaundice
Estrogens may be poorly metabolised in patients with impaired liver function (see CONTRAINDICATIONS). If jaundice develops in any patient receiving estrogen, the medication should be discontinued.

For patients with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, PREMARIN should be discontinued.

Angioedema
Exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.

Hypercalcaemia
PREMARIN should be used with caution in patients with metabolic bone disease that is associated with hypercalcaemia or in patients with renal insufficiency.

Hypocalcaemia
Estrogens should be used with caution in patients with severe hypocalcaemia, and in diseases that can predispose to severe hypocalcaemia.

Hypothyroidism
Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients dependent on thyroid replacement therapy, who are receiving estrogens, may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range (see Effect on laboratory tests).

Visual abnormalities
Retinal vascular thrombosis has been reported in patients receiving estrogens. Discontinue PREMARIN pending examination if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia or migraine. If examination reveals papilloedema or retinal vascular lesions, PREMARIN should be withdrawn.

Hypertriglyceridaemia
Caution should be exercised in patients with pre-existing hypertriglyceridaemia since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with estrogen therapy in this population. Women with pre-existing hypertriglyceridaemia should be followed closely during HRT.
Laboratory monitoring

Estrogen administration should be guided by clinical response instead of by hormone levels, e.g., estradiol, follicle stimulating hormone (FSH) (see Effects on laboratory tests).

Other

PREMARIN is not an oral contraceptive, nor will it restore fertility. If it is administered together with or without a progestogen to a woman of child bearing potential she should be advised to use non-hormonal methods of contraception.

Use in paediatrics

PREMARIN is not indicated for use in paediatrics. Safety and effectiveness in paediatric patients have not been established. Estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce uterine bleeding.

Since large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, hormonal therapy should not be started before epiphyseal closure has occurred in order not to compromise final growth.

Use in the elderly

The WHI estrogen alone substudy reported an increased risk of stroke compared with placebo in postmenopausal women 65 years of age or older (see PRECAUTIONS, Cardiovascular risk).

The estrogen alone substudy of the WHIMS, conducted in women aged 65-79, reported an increased risk of developing probable dementia for CE alone compared to placebo. It is unknown whether these findings apply to younger postmenopausal women (see CLINICAL TRIALS, Women’s Health Initiative Memory Study and PRECAUTIONS, Dementia).

Use in pregnancy: Category D

PREMARIN should not be used during pregnancy.

Use in lactation

Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of breast milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving the drug. Lactating mothers should not use PREMARIN.

Carcinogenicity

Studies suggest that combination HRT increases the risk of breast cancer, ovarian cancer and endometrial cancer in women in a time dependant manner (see PRECAUTIONS).

Long-term, continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, cervix, vagina and liver.

Effects on laboratory tests

Pathologists should be made aware that a patient is receiving HRT when relevant specimens are submitted.

Certain endocrine and liver function tests may be affected by administration of PREMARIN.
Accelerated prothrombin time, partial thromboplastin time and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.

Estrogens increase thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T₄ levels by column or by radioimmunoassay or T₃ levels by radioimmunoassay. T₃ resin uptake is decreased, reflecting the elevated TBG. Free T₄ and free T₃ concentrations are unaltered.

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG) leading to increased circulating corticosteroid and sex steroids respectively. Free or biologically active hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-trypsin, ceruloplasmin).

Impaired glucose tolerance.

The response to metyrapone test may be reduced.

Increased plasma HDL and HDL₁ cholesterol sub-fraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.

The results of these tests should not be regarded as reliable until estrogen use has been discontinued for 1-2 months. Abnormal tests results should then be repeated.

Gonadotropin levels.

Plasma cortisol levels.

Increased plasma estrogen levels.

INTERACTIONS WITH OTHER MEDICINES

Data from a drug-drug interaction study involving PREMARIN and medroxyprogesterone acetate indicate that the pharmacokinetic disposition of both medicines is not altered when the medicines are co-administered. Other clinical drug-drug interaction studies have not been conducted with PREMARIN.

*In vitro* and *in vivo* studies have shown that estrogens are metabolised partially by cytochrome P450 3A4 (CYP3A4). Therefore, CYP3A4 inducers or inhibitors may affect drug metabolism. Inducers of CYP3A4, such as St John’s wort (*Hypericum perforatum*) preparations, phenobarbitone, phenytoin, carbamazepine, rifampicin and dexamethasone may reduce plasma concentrations of estrogens. This may lead to a decreased effect and/or changes in the uterine bleeding profile. CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, cyclosporin, grapefruit juice, ketoconazole,itraconazole and ritonavir may increase plasma concentrations of estrogens and may result in side effects.

Hot flushes and vaginal bleeding have been reported in patients receiving hormone therapy and St John’s wort (*Hypericum perforatum*).
Alteration of the effectiveness of antihypertensive agents, theophyllines, phenothiazines, corticosteroids, tricyclic antidepressants, diazepam and caffeine, by either potentiating/enhancing their pharmacological effect or by decreasing their clearance may occur during estrogen use.

**ADVERSE EFFECTS**

The most serious adverse reactions associated with the use of PREMARIN are indicated under PRECAUTIONS. The following adverse reactions have been reported and are listed below in CIOMS frequency categories:

Adverse reactions as per CIOMS frequency categories:

- **Very common**: >10%
- **Common**: >1% and <10%
- **Uncommon**: >0.1% and <1%
- **Rare**: >0.01% and <0.1%
- **Very rare**: <0.01%
- **Unknown**: cannot be estimated from the available data.

**Adverse reactions by body system**

**Immune system disorders**
Uncommon: Hypersensitivity.
Rare: Urticaria, angioedema, anaphylactic/anaphylactoid reactions.

**Reproductive system and breast disorders**
Common: Abnormal uterine bleeding, breast pain, tenderness, enlargement, discharge, leucorrhoea.
Uncommon: Change in menstrual flow, change in cervical ectropion and secretion.
Rare: Dysmenorrhoea/pelvic pain, galactorrhoea, increased size of uterine leiomyomata.
Very rare: Endometrial hyperplasia
Unknown: Gynaecomastia in males.

**Gastrointestinal disorders**
Uncommon: Nausea, bloating, abdominal pain.
Rare: Vomiting, pancreatitis, ischaemic colitis.

**Hepatobiliary disorders**
Uncommon: Gallbladder disease.
Very rare: Cholestatic jaundice.

**Infections and infestations**
Uncommon: Vaginitis including vaginal candidiasis.

**Neoplasms benign and malignant (including cysts and polyps)**
Rare: Breast cancer, ovarian cancer, fibrocystic breast changes, growth potentiation of benign meningioma.
Very rare: Endometrial cancer, enlargement of hepatic hemangiomas.

**Musculoskeletal, connective tissue and bone disorders**

Common: Arthralgias, leg cramp.

**Psychiatric disorders**

Uncommon: Changes in libido, mood disturbances, depression, dementia.
Rare: Irritability.

**Skin and subcutaneous tissue disorders**

Common: Alopecia.
Uncommon: Chloasma/melasma, hirsutism, pruritus, rash.
Very rare: Erythema multiforme, erythema nodosum.

**Cardiac disorders**

Rare: Myocardial infarction.

**Vascular disorders**

Uncommon: Venous thrombosis, pulmonary embolism.
Rare: Superficial thrombophlebitis.

**Respiratory, thoracic and mediastinal disorders**

Rare: Exacerbation of asthma.

**General disorders and administration site conditions**

Uncommon: Oedema.

**Metabolism and nutrition disorders**

Rare: Glucose intolerance.
Very rare: Exacerbation of porphyria, hypocalcaemia (in patients with disease that can predispose to severe hypocalcaemia).

**Eye Disorders**

Uncommon: Intolerance to contact lenses.
Very rare: Retinal vascular thrombosis.

**Nervous System disorders**

Uncommon: Dizziness, headache, migraine, nervousness.
Rare: Cerebrovascular accident/stroke, exacerbation of epilepsy.
Very rare: Exacerbation of chorea.

**Investigations**

Common: Changes in weight (increase or decrease), increased triglycerides.
Very rare: Increase in blood pressure.
Ovarian cancer
Use of estrogen-only and or combined estrogen-progestogen HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see PRECAUTIONS, Ovarian cancer).

A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period.

**DOSAGE AND ADMINISTRATION**
Continuous daily administration of PREMARIN is generally recommended.

Patients should be re-evaluated periodically to determine if treatment for symptoms is still necessary. See the statements in PRECAUTIONS, General, Malignant neoplasm, Endometrial cancer and Cardiovascular risk and Dementia, particularly when considering PREMARIN for long-term usage.

Physicians should advise their patients that the tablets should be taken whole. The tablets should not be divided, crushed, chewed, or dissolved in the mouth.

PREMARIN tablets can be taken with or without food.

For women with an intact uterus, it is recommended that a progestogen is administered (see PRECAUTIONS, Malignant neoplasms). For continuous PREMARIN administration, a progestogen should be added for at least 10-14 consecutive days each month. In some cases, hysterectomised women with a history of endometriosis may need a progestogen (see PRECAUTIONS, Exacerbation of other conditions).

If PREMARIN is administered cyclically (i.e., 21 days out of 28 days), it is recommended that the progestogen is added for the last 10-14 days of the estrogen course.

**Climacteric symptoms**
For treatment of moderate-to-severe vasomotor symptoms and atrophic vaginitis associated with the menopause, the lowest dose that will control symptoms should be chosen.

*Vasomotor symptoms*

0.3 mg to 1.25 mg daily.

*Atrophic vaginitis*

0.3 mg to 1.25 mg daily, depending upon the tissue responses of the individual patient.

**For prevention of postmenopausal osteoporosis**
The minimum effective dose is 0.625mg daily for most patients.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated pharmacological therapy. Postmenopausal women require an adequate daily intake of elemental calcium. Therefore when not contraindicated, calcium supplementation may be helpful for women with sub-optimal dietary intake. Vitamin D supplementation may also be required to ensure adequate daily intake in postmenopausal women.

**Hypoestrogenism**

*Female hypogonadism*

2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on the responsiveness of the endometrium.

If bleeding occurs before the end of the 10-day period, begin a 20-day estrogen-progestogen cyclic regimen with PREMARIN, 2.5 to 7.5 mg daily in divided doses. During the last five days of estrogen therapy, give an oral progestogen. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding.

*Female castration and primary ovarian failure*

0.3 mg to 1.25 mg daily. Adjust dosage according to severity of symptoms and response of the patient.

**OVERDOSAGE**

Symptoms of overdose of estrogen-containing products in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; withdrawal bleeding may occur in females. There is no specific antidote and further treatment, if necessary, should be symptomatic.

Contact the Poisons Information Centre on 0800 764 766 for advice on the management of an overdose.

**PRESENTATION AND STORAGE CONDITIONS**

**Presentation**

Premarin 0.3 mg Tablets (dark green, marked 0.3) is supplied in blister packs of 28 tablets. Premarin 0.625 mg Tablets (maroon, marked 0.625) is supplied in blister packs of 28 tablets.

**Storage conditions**

Store below 25°C.

**MEDICINES CLASSIFICATION**

Prescription Medicine.
NAME AND ADDRESS

Pfizer New Zealand Limited
PO Box 3998
Auckland, New Zealand, 1140.
Toll Free Number: 0800 736 363.

DATE OF PREPARATION

18 July 2016.

* Registered trademark.